Eisai to discontinue antiobesity drug development
Eisai obtained the exclusive rights to develop and market KES524 in Japan in an agreement with Abbott. Eisai had submitted a MAA for the agent to the Japanese
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.